Literature DB >> 12614469

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

F Toccaceli1, V Laghi, L Capurso, M Koch, S Sereno, M Scuderi.   

Abstract

A retrospective multicentre survey was conducted to evaluate, in patients with chronic hepatitis C, the long-term liver histological changes induced by interferon (IFN). A total of 112 patients (mean age 46.4 years) were studied. All patients had received a 6-12-month IFN-alpha course (6-18 MU/week) and had successively undergone clinical, biochemical and virological follow-up for at least 36 months (range: 36-76). In each patient, two liver biopsies had been performed: 1-6 months before treatment and, 12-76 months after its completion. In 87 patients with biochemical and virological sustained response persisting for 12 months after therapy, post-treatment liver necroinflammation and fibrosis mean(+/-SD) scores (Knodell index) were significantly lower than pretreatment scores (2.9 +/- 2.2 vs 6.8 +/- 2.9 and 0.8 +/- 1.0 vs 1.2 +/- 1.1, respectively; P < 0.01). In 25 patients who relapsed within 1 year, necroinflammation and fibrosis post-treatment mean scores were similar to pretreatment scores (7.4 +/- 3.2 vs 6.9 +/- 3.1 and 1.8 +/- 1.3 vs 1.6 +/- 1.2, respectively; P > 0.05). On an individual basis, necroinflammation decreased in 87% of sustained responders but only in 36% of relapsers (P < 0.001), whereas fibrosis decreased in 44% of sustained responders but only in 14% of relapsers (P < 0.001). In sustained responders with biopsies performed 12-23 months (n=34), 24-35 months (n=26) or more than 36 months (n=27) after treatment, a progressive decrease of mean necroinflammatory score was observed (-2.6 +/- 2.1, -4.1 +/- 3.4 and -5.2 +/- 3.7 points, respectively; P < 0.01). A similar pattern was observed in fibrosis score (-0.3 +/- 0.6, -0.3 +/- 0.7 and -0.7 +/- 0.9 points, respectively; P < 0.05). Hence, among chronic hepatitis C patients treated with IFN, those with a 12-month sustained response, unlike those who relapse, have a long-term progressive reduction and, in some cases, a complete regression of liver histological damage.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614469     DOI: 10.1046/j.1365-2893.2003.00403.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  14 in total

Review 1.  Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis.

Authors:  Siddharth Singh; Antonio Facciorusso; Rohit Loomba; Yngve T Falck-Ytter
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-04       Impact factor: 11.382

2.  Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.

Authors:  Dariusz-Marek Lebensztejn; Maria-Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski; Michael Voelker; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients.

Authors:  Sarah L George; Bruce R Bacon; Elizabeth M Brunt; Kusal L Mihindukulasuriya; Joyce Hoffmann; Adrian M Di Bisceglie
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

4.  Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.

Authors:  Keisuke Osakabe; Naohiro Ichino; Toru Nishikawa; Hiroko Sugiyama; Miho Kato; Ai Shibata; Wakana Asada; Naoto Kawabe; Senju Hashimoto; Michihito Murao; Takuji Nakano; Hiroaki Shimazaki; Toshiki Kan; Kazunori Nakaoka; Yuka Takagawa; Masashi Ohki; Takamitsu Kurashita; Tomoki Takamura; Kentaro Yoshioka
Journal:  World J Gastroenterol       Date:  2015-09-21       Impact factor: 5.742

Review 5.  Chronic hepatitis C: This and the new era of treatment.

Authors:  Gaetano Bertino; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Shirin Demma; Maria Irene Ruggeri; Laura Scuderi; Giulia Malaguarnera; Nicoletta Bertino; Venerando Rapisarda; Isidoro Di Carlo; Adriana Toro; Federico Salomone; Mariano Malaguarnera; Emanuele Bertino; Michele Malaguarnera
Journal:  World J Hepatol       Date:  2016-01-18

Review 6.  Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness.

Authors:  Cristina Stasi; Stefano Milani
Journal:  World J Gastroenterol       Date:  2016-01-28       Impact factor: 5.742

7.  Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy.

Authors:  Rui Huang; Huiying Rao; Ming Yang; Yinghui Gao; Jian Wang; Qian Jin; Danli Ma; Lai Wei
Journal:  Dig Dis Sci       Date:  2019-10-25       Impact factor: 3.199

8.  LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients.

Authors:  Xia Zou; Xiumei Chi; Yu Pan; Dongning Du; Haibo Sun; Atsushi Matsuda; Wei Li; Atsushi Kuno; Xinxin Zhang; Hisashi Narimatsu; Junqi Niu; Yan Zhang
Journal:  Clin Proteomics       Date:  2014-12-11       Impact factor: 3.988

9.  Predicting Liver-Related Events Using Transient Elastography in Chronic Hepatitis C Patients with Sustained Virological Response.

Authors:  Hye Won Lee; Young Eun Chon; Seung Up Kim; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kyu Sik Jung; Young Nyun Park; Kwang-Hyub Han
Journal:  Gut Liver       Date:  2016-05-23       Impact factor: 4.519

Review 10.  APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Authors:  Masao Omata; Tatsuo Kanda; Lai Wei; Ming-Lung Yu; Wang-Long Chuang; Alaaeldin Ibrahim; Cosmas Rinaldi Adithya Lesmana; Jose Sollano; Manoj Kumar; Ankur Jindal; Barjesh Chander Sharma; Saeed S Hamid; A Kadir Dokmeci; Mamun Al-Mahtab; Geofferey W McCaughan; Jafri Wasim; Darrell H G Crawford; Jia-Horng Kao; Osamu Yokosuka; George K K Lau; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2016-05-26       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.